This article is more than 5 years old. Information may no longer be current.

Episurf Medical receives CE mark for personalized implant for cartilage damage

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Episurf Medical announced the company has met the CE marking requirements for its personalized implant, the Episealer Femoral Condyle, which treats cartilage damage in the knee.

According to a company press release, the launch will be rolled out in stages under controlled conditions to a limited number of qualified orthopaedics clinics in strategically selected European countries. While this first phase is underway, Episurf will continue to establish distribution contracts in other selected markets.

“The approval is an important milestone for the company, allowing us to launch products in Europe and bringing Episurf Medical into the first phase of commercialization,” Nina Bake, chief executive officer of Episurf Medical, stated in the release. “This new approval, in combination with a recent 70 million SEK rights issue and signed distribution contracts in Switzerland and Poland puts us in a strong position for our product launch this fall.”